The Latest
For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
New Study Shows Effectiveness of On-Demand PrEP
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
This Week in HIV Research: Setting a New Bar
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
This Week in HIV Research: The Long Road to the End
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
This Week in HIV Research: Resistance (Testing) Is Futile
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
This Week in HIV Research: Unlocking Secrets of Engagement in Care
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.